Physician profile
Charles E Nicholson
NPI 1215433867
$1,382.39
in general payments reported to CMS, 2019-2025
17 companies · $46.45 in 2025
The $46.45 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $395 · 2023: $614 · 2024: $77.14 · 2025: $46.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700 · Debt Forgiveness: $37.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.20 |
| Debt Forgiveness | $37.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $266.47 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $139.90 | 2022-2023 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Lilly USA, LLC | $116.66 | 2022-2023 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.37 | 2023 | Jardiance |
| Novo Nordisk INC | $85.90 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $84.78 | 2022-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $72.55 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $59.40 | 2023-2024 | |
| Glaxosmithkline, LLC. | $54.85 | 2023-2024 | Shingrix, Arexvy, Bexsero |
| Daiichi Sankyo INC. | $52.14 | 2022 | |
| Exact Sciences Corporation | $52.00 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $44.11 | 2022-2023 | Repatha, Otezla |
| Baxter Healthcare | $37.86 | 2023 | |
| Inspire Medical Systems, INC. | $37.24 | 2023-2024 | Inspire |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $35.92 | 2023 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $28.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.